I promise

"I promise, Suzy... Even if it takes the rest of my life." -Nancy G. Brinker, Founder of Susan G. Komen for the Cure

What is TNBC

WHAT IS TRIPLE NEGATIVE BREAST CANCER?

Just in recent years, Triple Negative Breast Cancer (TNBC) has sparked interest in the news where instead of calling the tumor as ER-negative, PR-negative, and HER2-negative; researchers began using the shorthand term, "Triple Negative," dubbed the "new type" of breast cancer. Being Triple Negative, you don't have a targeted therapy and your only treatment option is chemotherapy.

Triple Negative Breast Cancer is seen in about 15% of all breast cancers. TNBC is a very aggressive cancer that tends to strike younger women, pre-menopause, especially among African-American women and women who have BRCA1 mutations. The tumor tends to be fast growing and is less likely to show up on an annual mammogram. TNBC is more likely to metastasis early on; has a high rate of recurrence in the first 2-3 years from diagnosis and has a poorer prognosis than other types of breast cancer due to lack of specific, targeted treatment for TNBC.

Sunday, March 8, 2020

University of Toledo Football 2019

Thank you Dr. Tiwari for the special invite to watch UT football and discuss cancer research with your collaborators in your department's suite for the evening.

with University of Toledo researchers and
Mary Westphal, CEO of Komen of NW, Ohio

University of Toledo,
Department of Pharmacology and
Experimental Therapeutics suite 

Our sweet suite!

University of Toledo Football

Mary Westphal, CEO of Komen NW Ohio
Dr. Amit Tiwari,
Triple Negative Breast Cancer researcher
and Melissa, Patient Advocate Mentor

Total Pageviews



"click image to link"